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Summary table 25 
 
What is known about topic 
 
 Poor adherence is a well-recognised cause of 
apparently resistant hypertension. 
 Accurately measuring patient adherence has 
historically been very challenging.  
 Urine analysis by high-performance liquid 
chromatography-tandem mass spectrometry 
has recently become routinely available as a 
method of screening for non-adherence. 
 
What this study adds 
 The most common reasons for non-adherence 
were adverse effects of medication and 
forgetfulness. 
 Adherence rates for thiazide/thiazide-like 
diuretics and spironolactone were lower than 
for other classes of antihypertensive drug. 
 Approximately one third of non-adherent 
patients disputed their results. Further research 
on the effect this assay may have on the 
patient-clinician relationship is warranted.  
 26 
 27 
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 30 
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Abstract 32 
 33 
Poor adherence with pharmacotherapy is well recognised as one of the main barriers 34 
to achieving satisfactory blood pressure control, although accurately measuring 35 
patient adherence has historically been very challenging. Urine analysis by high-36 
performance liquid chromatography-tandem mass spectrometry has recently become 37 
routinely available as a method of screening for non-adherence. In addition to 38 
measuring rates of adherence in hypertensive patients, this study aimed to investigate 39 
the reasons for non-adherence given by patients and how patients react when they are 40 
informed of their results. This was a retrospective observational study looking at 41 
results from the routine use of this assay in a specialist hypertension clinic in 42 
Birmingham, UK, in patients with uncontrolled hypertension and those under 43 
consideration for renal denervation. Out of the 131 patients analysed, only 67 (51%) 44 
were taking all their medications as prescribed. Forty-three patients (33%) were 45 
taking some of their medications, whilst 21 patients (16%) were completely non-46 
adherent. The most common reasons cited for non-adherence were adverse effects of 47 
medication and forgetfulness. Adherence rates for thiazide/thiazide-like diuretics and 48 
spironolactone were lower than for other classes of antihypertensive drug. Despite the 49 
objective nature and high sensitivity of the test, 36% of non-adherent patients 50 
disputed the results. A minority of patients did not attend follow-up. Further research 51 
investigating the implications of a ‘non-adherence’ result on the patient-clinician 52 
relationship is required. 53 
 54 
 55 
 56 
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Introduction 57 
 58 
Although effective and well-tolerated once-daily antihypertensive medications are 59 
widely available, poor adherence with recommended treatments continues to be one 60 
of the main barriers to satisfactory blood pressure (BP) control (1, 2). A recent meta-61 
analysis of data on more than 376,000 patients from 20 studies assessing drug 62 
adherence for seven preventative drug classes (including five antihypertensive drug 63 
classes), found that the mean adherence over all studies was only 57% after a median 64 
of two years (3). A longitudinal study by Vrijens et al using a database of over 4700 65 
patients prescribed once a day antihypertensive medication from 21 phase IV clinical 66 
studies, demonstrated that by the end of one year, almost half of the patients had 67 
stopped taking their antihypertensive medication (4).  68 
 69 
Measurement of patient adherence has historically been very challenging, and as a 70 
result, suboptimal adherence to a prescribed drug regimen often goes unrecognised in 71 
everyday clinical practice. One of the main problems with measuring behaviours such 72 
as adherence is that the act of measurement itself can have some bearing on the 73 
behaviour, the so-called Hawthorne effect. If patients are aware their medication-74 
taking is being monitored, this in itself can stimulate adherence (5). Consequently, 75 
patients underreport non-adherence and also take medication immediately prior to 76 
testing or clinic appointments, so-called ‘white coat adherence’ (6). Conversely, 77 
clinical judgement alone is believed to overestimate the rate of non-adherence to 78 
antihypertensive medication (7). 79 
 80 
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Adherence can be measured directly or indirectly. Direct measurement involves either 81 
observing ingestion of the drug or by detecting its presence in plasma or urine. 82 
Indirect measures assume ingestion based on proxy-evidence such as self-reporting or 83 
number of dosages removed from a container (5). Traditional methods of measuring 84 
adherence (computerised records of prescription pharmacy refills, pill counts, 85 
questionnaires, patients’ diaries) are inexpensive but have severe limitations and have 86 
been shown to overestimate it (8). Electronic monitoring methods such as the 87 
medication event monitoring system (MEMS; AARDEX Group, Ltd, Sion, 88 
Switzerland) have been regarded as the gold standard for monitoring adherence in 89 
clinical trials, because of their automaticity and precision of timing when patients take 90 
or omit doses. Although MEMS is based on an indirect measurement, it has been 91 
extensively validated and used in drug trials since 1988, including several studies 92 
conducted in the field of hypertension (8). Biochemical methods of testing can detect 93 
whether a drug has been ingested but until recently have been considered relatively 94 
costly. They are highly sensitive but cannot provide any information on when doses 95 
were taken or omitted and are affected by the white coat adherence phenomenon. 96 
Urine analysis by high-performance liquid chromatography-tandem mass 97 
spectrometry (HP LC-MS/MS) has recently come to the fore as a useful method of 98 
screening for non-adherence in hypertensive patients (9). A group at the University of 99 
Leicester in the United Kingdom were among the first to develop this test that is able 100 
to screen for 52 of the most commonly prescribed antihypertensive drugs or their 101 
metabolites using a random urine sample. The test is inexpensive and we have been 102 
using this test in routine clinical practice in the hypertension clinic at University 103 
Hospitals Birmingham NHS Foundation Trust since November 2013. Studies 104 
published to date making use of such an assay to measure adherence rates have not 105 
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looked at the reasons for non-adherence or whether adherence rates change on 106 
subsequent testing. How patients react when they are informed of their results and 107 
what explanations they give for not taking their medications are two of the questions 108 
we hoped to answer with this retrospective observational study. Subsequent work will 109 
aim to investigate the potential implications this assay can have on medication taking 110 
behaviour and on the patient-clinician relationship.  111 
 112 
Materials and Methods 113 
 114 
This was a retrospective observational study looking at results from the routine use of 115 
urine adherence testing in the hypertension clinic at University Hospitals Birmingham 116 
NHS Foundation Trust, which receives referrals from primary and secondary care 117 
physicians in the West Midlands for investigation and management of patients with 118 
uncontrolled hypertension. Following consultation with a hypertension specialist, 119 
patients were asked to provide a urine sample for analysis. Patients included all those 120 
being worked-up for consideration of renal denervation and those with uncontrolled 121 
and apparently ‘resistant’ hypertension in whom non-adherence needed to be 122 
excluded. By definition, patients with resistant hypertension included those with BP 123 
that was not controlled to target, that is, a clinic systolic BP of greater than 140 124 
mmHg and/or diastolic BP greater than 90 mmHg, despite treatment with at least 125 
three antihypertensive medications (usually including a diuretic). Following 126 
explanation that their urine would be tested for the presence of their prescribed blood 127 
pressure medicines, patients were asked to provide a random urine sample for 128 
analysis. Prior to attending clinic, patients were not given any warning about this test 129 
in order to exclude white coat adherence. Patients provided verbal consent and none 130 
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refused. Samples were frozen at minus 20°C and sent to University Hospitals of 131 
Leicester NHS Trust pathology department for analysis. Samples were analysed using 132 
HPLC-MS/MS for the presence of antihypertensive drugs or their metabolites. The 133 
technique has been described in detail elsewhere (9). Data on all patients undergoing 134 
the test during a two year period between November 2013 and November 2015 was 135 
collected retrospectively from electronic patient records. This included 131 patients in 136 
total. Data collected included: basic demographics, the names of prescribed 137 
antihypertensive medications, the reason for the test being carried out, and the 138 
medications detected in the urine sample. Data on the response of the patient when 139 
informed of the results and the reasons given by the patient for non-adherence (when 140 
applicable) were obtained from electronic clinic letters. Because this information was 141 
collected retrospectively, some information was lacking in a minority of patients.  142 
 143 
Results 144 
 145 
One-hundred-and-thirty-one urine samples from 131 patients were analysed. The 146 
median number of antihypertensive drugs prescribed was 4 (IQR 3-5; mean 4.14); the 147 
median number of drugs detected in the urine was 3 (IQR 1-4; mean 2.76) (Figure 1).  148 
 149 
In five cases, when furosemide was the only drug not detected in the urine, it was 150 
deemed not to be clinically significant by the investigators due to its short half-life, 151 
and these five patients were considered to be adherent. Only 67 patients out of the 131 152 
(51%) were taking all their medications as prescribed (‘adherent’); 43 patients (33%) 153 
were taking some of their prescribed medications and therefore deemed ‘partially 154 
adherent’ with their treatment; 21 patients (16%) were not taking any of their 155 
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medications and were categorised as ‘completely non-adherent’ (Figure 2). Out of 122 156 
patients with uncontrolled hypertension prescribed 3 or more drugs (including a 157 
diuretic in 106 cases), only 55 (45%) were completely adherent with prescribed 158 
medications and could be deemed truly ‘resistant’.  159 
 160 
When patients were separated into ‘new referrals’ and ‘follow-up’ categories, a 161 
significant difference in adherence was observed: adherent 38% versus 59%; partially 162 
adherent 38% versus 30%; non-adherent 25% versus 11%; Kendall’s tau-b 0.219, p= 163 
0.009.   164 
 165 
From the 64 patients categorised as partially or completely non-adherent, six patients 166 
did not attend follow-up after providing the urine sample. When the remaining 58 167 
patients were presented with their results, 25 admitted to non-adherence (43%), whilst 168 
21 denied non-adherence (36%) and disputed the result according to documentation in 169 
electronic clinic letters (Table 1). Twelve patients (21%) neither denied nor admitted 170 
it and it was unclear as to the reasons for non-adherence. The reaction was not known 171 
in the non-attenders.  172 
 173 
Out of the 25 patients who admitted non-adherence, the most common reason cited in 174 
the clinic letter was adverse effects of medication (9 patients; 36%), closely followed 175 
by forgetfulness (8 patients; 32%); in 6 cases there was no documented reason given. 176 
Other explanations included running out of medication, misunderstanding 177 
instructions, prescription cost and apathy (Table 2).  178 
 179 
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In the 12 cases where non-adherence was neither admitted nor denied, a language 180 
barrier was felt to be the main factor behind non-adherence in six cases (lack of 181 
English was noted in the clinic letters). In five cases there was no documentation of 182 
patient reaction in the notes, and in one case a carer had been administering the 183 
medication.   184 
 185 
Data from the detection rates with the most commonly prescribed classes of 186 
antihypertensive drugs were analysed, which can be seen in Table 3. Adherence rates 187 
for thiazide/thiazide-like diuretics, including indapamide, bendroflumethiazide and 188 
hydrochlorothiazide (53.95%) and the aldosterone antagonist spironolactone (47.83%) 189 
were lower than for other classes of antihypertensive drug. 190 
 191 
We also analysed adherence rates according to the number of antihypertensive drugs 192 
prescribed (Figure 3). There was a trend towards decreasing adherence rates with the 193 
higher number of drugs prescribed, although this did not reach statistical significance 194 
(p=0.115) because the vast majority of patients were prescribed between three and 195 
five antihypertensive drugs (109 out of 131, 83%) and similar rates of adherence 196 
(approximately 50%) were observed in those patients.   197 
 198 
Discussion 199 
 200 
Direct measurement of adherence in hypertensive patients by urine analysis using HP 201 
LC-MS/MS is a highly effective method of establishing whether patients are taking 202 
their blood pressure medications as prescribed. In the study by Tomaszewski et al 203 
making use of this method to analyse the urine of hypertensive patients at a specialist 204 
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hypertension clinic in Leicester, 25% of the 208 patients who underwent screening 205 
were found to be partially or completely non-adherent (9). However, they included all 206 
new referrals and follow-up patients. In our routine clinical practice, we are more 207 
selective in whom we test as the assay is mainly used to investigate for non-adherence 208 
in those most likely to be non-adherent i.e. those with uncontrolled hypertension 209 
apparently refractory to drug treatment. In this retrospective observational study, 210 
overall, we found that approximately half of the patients were taking their 211 
medications as prescribed (51%). Patients were not given any prior warning about the 212 
test, reducing the likelihood of the white coat adherence phenomenon confounding the 213 
results, a strength of this study. This study confirms that poor adherence with 214 
prescribed treatment remains one of the most important causes of failing to achieve 215 
target blood pressure. A significant proportion of patients were not taking any of their 216 
antihypertensive medications (16%). This is a high figure due to the selectivity of 217 
patients in whom the test is used as a screening method and does not reflect the true 218 
prevalence of complete non-adherence in the clinic. The most extreme case included 219 
one patient who was referred to the clinic having been prescribed ten antihypertensive 220 
medications under the care of a cardiologist, none of which were detected in his urine. 221 
When analysing only the patients with uncontrolled hypertension prescribed three or 222 
more drugs (usually including a diuretic), 55% were found to be partially or 223 
completely non-adherent. This finding is very similar to a previous study using a 224 
similar methodology, which found approximately half (53%) of patients with apparent 225 
resistant hypertension were non-adherent (10). In light of this finding, our view is that 226 
urine adherence testing should become routine when managing patients with apparent 227 
resistant hypertension because patients with true resistance warrant meticulous 228 
investigation for secondary causes. Such investigations are expensive, time-229 
 11 
consuming and potentially involve radiation exposure. In patients with confirmed 230 
poor adherence, such tests may be completely unnecessary and the focus can be 231 
shifted towards optimising adherence.  232 
 233 
Previous studies using urine analysis to measure adherence have not looked at how 234 
such patients react when they are informed of the results, or the reasons given for not 235 
taking their medications. It was noted from the present study that when informed of 236 
the results of their urine tests, patients acted in different ways. Despite the objective 237 
nature of the test, and explanation to the patient of its high sensitivity, about 30% of 238 
non-adherent patients denied that they were not taking their medications. Whether this 239 
represents a refusal to admit the truth, a false negative test result or simply a 240 
misunderstanding is not known. However, anecdotal evidence suggests that even 241 
when patients disputed the result, they were usually open to the suggestion of starting 242 
treatment afresh with a single BP agent, indicating that there was actually an issue 243 
with the number of medications they were prescribed. When a patient did admit to 244 
non-adherence, treatment could then be tailored to that particular individual with an 245 
emphasis on ways to improve adherence. It is important not to appear judgemental in 246 
this situation. Good relationships between healthcare providers and their patients are 247 
essential for good adherence. Some of the most important attributes that have 248 
previously been shown to be determinants of adherence in patients include an 249 
empathetic and non-judgemental attitude, ready availability and good quality of 250 
communication (11).  251 
 252 
A multitude of different factors have been shown to contribute to poor adherence. 253 
Two important features specific to hypertension include the asymptomatic and 254 
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lifelong nature of the disease itself. In keeping with this, the most common 255 
explanations given for non-adherence in the present study were adverse effects and 256 
forgetfulness. Memory and recall are well-known obstacles to good adherence. 257 
Simply forgetting to take the medicine at the right time, or poor recall of prescription 258 
instructions are both common (5). A study in 1979 by Anderson et al showed that 259 
patients could recall less than 50% of prescription instructions (12), and memory 260 
performance has subsequently been found to correlate with reduced adherence across 261 
a number of chronic diseases (13). There are other well-recognised issues relating to 262 
the drug therapy of hypertension, including drug tolerability, treatment duration, drug 263 
costs and complexity of the treatment regimen (11, 14). Regimen complexity is an 264 
important cause of non-adherence. Number of doses per day has been shown in a 265 
systematic review to be inversely related to adherence; adherence was significantly 266 
higher for once-daily compared with multiple-daily dosing (15). Because regimen 267 
complexity is a barrier that tends to reduce adherence, use of once-daily long-acting 268 
substances can improve adherence (15). However, the pharmacokinetics of a twice-269 
daily dosing regimen actually confers better maintenance of drug action despite a 270 
higher percentage of omitted doses (8). A Cochrane review on interventions for 271 
improving adherence to treatment in patients with high blood pressure in ambulatory 272 
settings showed that simplification of dosing regimens increased adherence in seven 273 
out of nine studies (16), although only one study reported an increase in adherence 274 
together with a reduction in blood pressure (17). Fixed-dose combinations have been 275 
frequently proposed as a strategy for improving adherence in patients with 276 
cardiovascular disease. There are obvious advantages in reducing the pill burden but 277 
drawbacks too. For example, missing one dose means several drugs are omitted, doses 278 
cannot be easily titrated, combinations are fixed and they are more expensive. In the 279 
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UMPIRE randomised controlled trial, use of a fixed dose combination of aspirin, 280 
simvastatin and two blood pressure lowering drugs did result in improved adherence 281 
compared with the usual care group (86% vs 65%; relative risk of being adherent, 282 
1.33 95% CI, 1.26-1.41; p <0.001), but this did not translate into a reduction in 283 
cardiovascular events or serious adverse events (18). Although the effect of dosing 284 
frequency on adherence was not analysed in our study, we were able to establish a 285 
trend towards decreasing adherence rates with the higher number of drugs prescribed. 286 
This did not reach statistical significance (p=0.115) because most patients in our study 287 
were prescribed 3-5 antihypertensive drugs, with only a minority of patients 288 
prescribed fewer than three antihypertensive drugs or greater than five. Our study did 289 
show that new referrals were less likely to be fully adherent and more likely to be 290 
completely non-adherent to their medications than follow-up patients. Reasons for the 291 
better rates of adherence shown in the follow-up patients are multifactorial but likely 292 
to be significantly contributed to by the closer attention to adherence these patients 293 
receive in the hypertension clinic.     294 
 295 
Patients’ beliefs and perceptions are also very important when it comes to adherence. 296 
Studies involving patients with a wide range of medical conditions have found that 297 
high rates of non-adherence are related to doubts about personal need for medication 298 
and concerns about potential side effects (5, 19, 20). Beliefs about the illness, 299 
perceptions of pharmaceuticals, expectations and experiences of symptoms all 300 
influence patients’ behaviour with regard to medicine taking (5). These beliefs may 301 
change over time. Patients often ‘test’ their need for the medication by altering the 302 
dose or taking a ‘drug holiday’ and monitoring the effects (21). Such drug holidays 303 
may or may not be detected with urine testing, depending on the timing of events. 304 
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Although the urine test can be affected by white coat adherence, it is unlikely that any 305 
of the patients were aware of the test when it was first performed, prior to attending 306 
the clinic. Subsequent testing may be affected by this phenomenon as patients became 307 
wise to the test and this is an area that offers the opportunity for further research.   308 
 309 
When looking at the most commonly prescribed classes of antihypertensive drugs, 310 
adherence rates for thiazide/thiazide-like diuretics (53.95%) and the aldosterone 311 
antagonist spironolactone (47.83%) were substantially lower than for other classes of 312 
antihypertensive drugs, which were all around 70%. This observation is consistent 313 
with a large observational study which showed that patients initiating treatment with 314 
angiotensin receptor blockers had a dramatically lower likelihood of early non-315 
persistence (stopping the medication) compared with patients initiated on diuretics 316 
(22). Diuretics are highly effective antihypertensive drugs and patients with resistant 317 
hypertension often benefit from intensification of diuretic therapy, including the 318 
addition of an aldosterone antagonist. However, adverse effects may lead to non-319 
adherence so it is important to encourage patients to be open and honest if they are 320 
experiencing intolerable side effects. Direct questioning about commonly experienced 321 
adverse effects are encouraged and substitutions made if an issue is highlighted.  322 
 323 
In our clinic, no patients have so far refused to have the test performed. However, six 324 
patients who were found to be non-adherent did not attend their follow-up 325 
appointment, and speculatively, this could be because they feared the doctor’s 326 
response or felt guilty about not taking their tablets. The test may have been the 327 
reason for the patient not attending but this is not known and it was only a small 328 
minority of patients. Further research is required into what implications this assay 329 
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might have on the patient-clinician relationship and we intend to explore this in 330 
subsequent projects using quantitative and qualitative methodologies.  331 
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Figure legends 414 
 415 
Figure 1: Box-and-whisker plot comparing the median number of antihypertensive 416 
medications prescribed with the median number detected in the urine in this group of 417 
patients with uncontrolled hypertension.  418 
 419 
Figure 2: Pie-chart showing percentage of patients in this cohort who were adherent, 420 
partially adherent, and completely non-adherent with their antihypertensive 421 
medication.  422 
 423 
Table 1: Table showing non-adherent patients’ reactions when presented with their 424 
urine test results. 425 
 426 
Table 2: Table showing patients’ explanations for non-adherence. 427 
 428 
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Table 3: Adherence rates with the seven most commonly prescribed antihypertensive 429 
drug classes in the clinic. ACE = angiotensin converting enzyme; ARB = angiotensin 430 
receptor blocker; CCB = calcium channel blocker.  431 
 432 
Figure 3: Graph showing percentage of patients who were fully adherent according to 433 
the number of antihypertensive drugs they were prescribed.   434 
 435 
